Charles Chiu

Dr. Chiu currently heads a translational research laboratory focused on clinical next-generation sequencing assay development for diagnosis of infectious diseases and investigation of emerging pathogens, including Borrelia burgdorferi (Lyme disease), Zika virus, and enterovirus D-68 in association with acute flaccid myelitis in children. Most recently, he His work also encompasses clinical and public health applications of nanopore sequencing and machine learning-aided RNA-Seq approaches to detect and identify diagnostic profiles of a patient’s response to infection. Dr. Chiu supported by funding from the National Institutes of Health (NIH), Abbott Laboratories, Department of Defense, NASA/Translational Research Institute, philanthropic grants (Charles and Helen Schwab and Steven and Alexandra Cohen Foundations), and the California Initiative to Advance Precision Medicine. He has authored more than 80 peer-reviewed publications, holds over 15 patents and patent applications, and serves on the scientific advisory boards for the Bay Area Lyme Foundation, Global Lyme Alliance, Therabio, Inc., and Mammoth Biosciences, Inc.